Sugi Predict

Sugi Predict / Compounds / SCHEMBL1346797

SCHEMBL1346797

SCHEMBL1346797

NS(=O)(=O)c1cc(Br)c(F)cc1F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 15/20 0.48
▸ CA1 P00915 12/20 0.48
▸ CA12 O43570 5/20 0.48
▸ CA7 P43166 4/20 0.48
▸ CA13 Q8N1Q1 2/20 0.48
▸ CA9 Q16790 10/20 0.45
▸ CA4 P22748 4/20 0.43
▸ CA6 P23280 4/20 0.43
▸ CA3 P07451 3/20 0.39
▸ CA5A P35218 3/20 0.39
▸ CA14 Q9ULX7 3/20 0.39
▸ CA5B Q9Y2D0 3/20 0.39
▸ APEX1 P27695 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ KDM1A O60341 2/20 0.35
▸ KCNH2 Q12809 2/20 0.35
▸ KDM1B Q8NB78 1/20 0.35
▸ TET2 Q6N021 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1510826 0.91 CA2 (0.45) CA2CA1CA12CA7CA13
SCHEMBL29835219 0.85 CA2 (0.52) CA2CA1CA12CA7CA13
SCHEMBL1137624 0.85 CA2 (0.52) CA2CA1CA12CA7CA13
SCHEMBL19000837 0.85 CA2 (0.46) CA2CA1CA12CA7CA13
SCHEMBL18152671 0.83 KDM4E (0.41) CA2CA1CA12CA7CA13
SCHEMBL15524948 0.83 POLB (0.41) CA2CA1CA12CA7CA13
SCHEMBL1349380 0.82 CA1 (0.35) CA2CA1CA12CA7CA13
SCHEMBL21633472 0.82 CCR2 (0.37) CA2CA1CA12CA7CA13
SCHEMBL18152704 0.80 CA2 (0.38) CA2CA1CA12CA7CA13
SCHEMBL23358172 0.79 CA2 (0.34) CA2CA1CA12CA7CA13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260092053-A1 KHK INHIBITORS GILEAD SCIENCES INC (US) 2026-04-02 — — US disclosed
EP-4681774-A2 KHK INHIBITORS Gilead Sciences, Inc. (US) 2026-01-21 — — EP disclosed
EP-4313967-B1 KHK INHIBITORS GILEAD SCIENCES INC (US) 2025-11-12 — — EP disclosed
US-12410160-B2 KHK inhibitors GILEAD SCIENCES, INC. (US) 2025-09-09 — — US disclosed
EP-4313967-A1 KHK INHIBITORS GILEAD SCIENCES, INC. (US) 2024-02-07 — — EP disclosed
CN-117120429-A KHK inhibitor 吉利德科学公司 2023-11-24 — — CN disclosed
US-20230079863-A1 KHK INHIBITORS GILEAD SCIENCES, INC. 2023-03-16 — — US disclosed
WO-2022212194-A1 KHK INHIBITORS GILEAD SCIENCES, INC. (US) 2022-10-06 — — WO disclosed
WO-2014170793-A1 SULFONAMIDES FOR THE TREATMENT OF GOUT PFIZER LIMITED (GB) 2014-10-23 — — WO disclosed
US-20140315933-A1 CHEMICAL COMPOUNDS PFIZER LIMITED (GB) 2014-10-23 — — US disclosed
US-20080300250-A1 ACETYLENYL-PYRAZOLO-PYRIMIDINE DERIVATIVES GATTI MCARTHUR SILVIA 2008-12-04 — — US disclosed
US-7446113-B2 Acetylenyl-pyrazolo-pyrimidine derivatives HOFFMAN-LA ROCHE INC. (US) 2008-11-04 — — US disclosed
CN-101180299-A Ethynyl-pyrazolopyrimidine derivatives as MGLUR2 antagonists HOFFMANN LA ROCHE (CH) 2008-05-14 — — CN disclosed
EP-1863818-A1 ACETYLENYL-PYRAZOLO-PVRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2007-12-12 — — EP disclosed
US-20070232583-A1 Pyridine and pyrimidine derivatives as mGIuR2 antagonists HOFFMANN-LA ROCHE INC. 2007-10-04 — — US disclosed
WO-2007110337-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2007-10-04 — — WO disclosed
US-20070167460-A1 Acetylenyl-pyrazolo-pyrimidine derivatives MCARTHUR SILVIA G 2007-07-19 — — US disclosed
US-7238808-B2 Acetylenyl-pyrazolo-pyrimidine derivatives HOFFMANN-LA ROCHE INC. (US) 2007-07-03 — — US disclosed
US-20060217387-A1 Acetylenyl-pyrazolo-pyrimidine derivatives F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2006-09-28 — — US disclosed
WO-2006099972-A1 ACETYLENYL-PYRAZOLO-PVRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2006-09-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315933-A1 CHEMICAL COMPOUNDS SULT2A1, SULT1A1, SULT1E1 CA2 1930/4885CA1 2209/4885CA12 3661/4885
US-20070232583-A1 Pyridine and pyrimidine derivatives as mGIuR2 antagonists P2RX2, P2RY2, P2RX1 CA2 2101/4885CA1 4351/4885CA12 4707/4885
US-20080300250-A1 ACETYLENYL-PYRAZOLO-PYRIMIDINE DERIVATIVES NAT1, TPMT, ACAT1 CA2 4071/4885CA1 3680/4885CA12 4483/4885
US-20060217387-A1 Acetylenyl-pyrazolo-pyrimidine derivatives NAT1, TPMT, ACAT1 CA2 4071/4885CA1 3680/4885CA12 4483/4885
US-20070167460-A1 Acetylenyl-pyrazolo-pyrimidine derivatives NAT1, ADORA2B, TPMT CA2 4055/4885CA1 3798/4885CA12 4565/4885
US-20260092053-A1 KHK INHIBITORS KHK, SLC5A2, HK1 CA2 2673/4885CA1 4798/4885CA12 4596/4885
US-20230079863-A1 KHK INHIBITORS KHK, KHDRBS1, NADK CA2 3700/4885CA1 4774/4885CA12 4528/4885
US-12410160-B2 KHK inhibitors KHK, KHDRBS1, NADK CA2 3700/4885CA1 4774/4885CA12 4528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.